# Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder

> **NCT02351869** · PHASE2 · TERMINATED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 25 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Nitrous Oxide
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT02351869
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2020-02-01
- **Final completion:** 2020-06-07
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** This study was terminated due to COVID-19 pandemic-related halting of recruitment in the context of an upcoming replacement of the study MRI scanner.
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02351869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02351869, "Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02351869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*